Judy Chou, PhD

Dr. Judy Chou is the CEO, President and Board member of AltruBio, Inc., a clinical stage biotech company. Previously, she headed the global Biotech organization at Bayer Pharmaceuticals overseeing the development, manufacturing and distribution of Bayer’s biotechnology pipeline, product portfolio & 2000+ employees. She also served as site head for Bayer’s facility in Berkeley, CA. She is recognized by the biomedical industry for her leadership and received the Most Influential Women in Business Award in 2018 by San Francisco Business Times. Before Bayer, Dr. Chou held the role of VP of Pharmaceutical Operations at Pfizer/Medivation and was also VP of R&D and Manufacturing at Tanvex Biopharma and has enabled the success of the company’s IPO. Dr. Chou has achieved significant milestones in biologics development and multiple filings of BLAs, NDAs, and INDs of novel products and is recognized for her work at Genentech, Pfizer (Wyeth) and Abbvie (Abbott). Currently, Dr. Chou also serves as the Board of Directors of Akero Therapeutics, Inc. and California Institute of Regenerative Medicines (CIRM). Previously, Dr. Chou was a research faculty member at Harvard University Medical School. Dr. Chou obtained her Ph.D. from Yale University and completed her post-doctoral training at Max-Planck Institute in Germany.